Fulltext

European cancer mortality predictions for the year 2012

Malvezzi, M. ; Bertuccio, P. ; Levi, F. ; La Vecchia, C. ; Negri, E.

In: Annals of Oncology, 2012, vol. 23, no. 4, p. 1044-1052

Ajouter à la liste personnelle
    Titre
    • European cancer mortality predictions for the year 2012
    Auteur
    • Malvezzi, M.. Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri”, Milan
    • Bertuccio, P.. Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri”, Milan
    • Levi, F.. Cancer Epidemiology Unit & Vaud and Neuchâtel Cancer Registries, Institute of Social and Preventive Medicine (IUMSP), Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland
    • La Vecchia, C.. Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri”, Milan
    • Negri, E.. Department of Epidemiology, Istituto di Ricerche Farmacologiche "Mario Negri”, Milan
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2012, vol. 23, no. 4, p. 1044-1052. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:294620
    Summary
    Background: Estimating current cancer mortality figures is important for defining priorities for prevention and treatment. Materials and methods: Using logarithmic Poisson count data joinpoint models on mortality and population data from the World Health Organization database, we estimated numbers of deaths and age-standardized rates in 2012 from all cancers and selected cancer sites for the whole European Union (EU) and its six more populated countries. Results: Cancer deaths in the EU in 2012 are estimated to be 1 283 101 (717 398 men and 565 703 women) corresponding to standardized overall cancer death rates of 139/100 000 men and 85/100 000 women. The fall from 2007 was 10% in men and 7% in women. In men, declines are predicted for stomach (−20%), leukemias (−11%), lung and prostate (−10%) and colorectal (−7%) cancers, and for stomach (−23%), leukemias (−12%), uterus and colorectum (−11%) and breast (−9%) in women. Almost stable rates are expected for pancreatic cancer (+2-3%) and increases for female lung cancer (+7%). Younger women show the greatest falls in breast cancer mortality rates in the EU (−17%), and declines are expected in all individual countries, except Poland. Conclusion: Apart for lung cancer in women and pancreatic cancer, continuing falls are expected in mortality from major cancers in the EU